background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

BiTE® PLATFORM

Amgen is the pioneer of BiTE® (Bispecific T-cell Engager) technology, which is designed to overcome cancer cells’ evasion of the immune system by engaging patients’ own T cells to directly target cancer cells.1,2 BiTE® molecules are engineered from two flexibly linked, single-chain antibodies, with one designed to specifically target a selected tumor-associated antigen and the other targeting CD3 found on T cells.2 This versatile technology is engineered with the goal of delivering off-the-shelf therapies that direct patients‘ own T cells to target any tumor-associated antigen, activating their cytotoxic potential.2,3

The BiTE® immuno-oncology platform has been studied in thousands of patients, and continues to be investigated across multiple different hematologic diseases and solid tumors.1,4

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CD, cluster of differentiation; DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin's lymphoma; R/R, relapsed or refractory.

References
1. Yuraszeck T, et al. Clin Pharmacol Ther. 2017;101:634-645. 2. Baeuerle PA, et al. Curr Opin Mol Ther. 2009;11:22-30. 3. Frankel SR, et al. Curr Opin Chem Biol. 2013;17:385-392. 4. Data on file, Amgen; 2019. 5. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03476239. Accessed 9/10/20. 7. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03117621. Accessed 9/10/20. 8. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02961881. Accessed 9/10/20. 9. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03340766. Accessed 9/10/20.
Molecule
Modality5
Target5
Areas of Investigation5
AMG 330
Modality5
BiTE® PLATFORM
Target5
Areas of Investigation5
Molecule
Modality5
Target5
Areas of Investigation6-9
Blinatumomab
Modality5
BiTE® PLATFORM
Target5
Areas of Investigation6-9

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CD, cluster of differentiation; DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin's lymphoma; R/R, relapsed or refractory.

References
1. Yuraszeck T, et al. Clin Pharmacol Ther. 2017;101:634-645. 2. Baeuerle PA, et al. Curr Opin Mol Ther. 2009;11:22-30. 3. Frankel SR, et al. Curr Opin Chem Biol. 2013;17:385-392. 4. Data on file, Amgen; 2019. 5. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03476239. Accessed 9/10/20. 7. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03117621. Accessed 9/10/20. 8. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02961881. Accessed 9/10/20. 9. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03340766. Accessed 9/10/20.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.